IL85897A0 - Method of diagnosing obesity caused by a genetic abnormality - Google Patents

Method of diagnosing obesity caused by a genetic abnormality

Info

Publication number
IL85897A0
IL85897A0 IL85897A IL8589788A IL85897A0 IL 85897 A0 IL85897 A0 IL 85897A0 IL 85897 A IL85897 A IL 85897A IL 8589788 A IL8589788 A IL 8589788A IL 85897 A0 IL85897 A0 IL 85897A0
Authority
IL
Israel
Prior art keywords
genetic abnormality
adipsin
obesity caused
abnormality
diagnosing obesity
Prior art date
Application number
IL85897A
Other languages
English (en)
Original Assignee
Beth Israel Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital filed Critical Beth Israel Hospital
Publication of IL85897A0 publication Critical patent/IL85897A0/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/044Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL85897A 1987-04-02 1988-03-29 Method of diagnosing obesity caused by a genetic abnormality IL85897A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3420387A 1987-04-02 1987-04-02

Publications (1)

Publication Number Publication Date
IL85897A0 true IL85897A0 (en) 1988-09-30

Family

ID=21874944

Family Applications (1)

Application Number Title Priority Date Filing Date
IL85897A IL85897A0 (en) 1987-04-02 1988-03-29 Method of diagnosing obesity caused by a genetic abnormality

Country Status (13)

Country Link
EP (2) EP0382720B1 (es)
JP (1) JPH02503229A (es)
AT (1) ATE80465T1 (es)
AU (1) AU606946B2 (es)
DE (1) DE3874543T2 (es)
DK (1) DK675388D0 (es)
ES (1) ES2046325T3 (es)
FI (1) FI894592A (es)
GR (1) GR3005716T3 (es)
IL (1) IL85897A0 (es)
NO (1) NO885360L (es)
WO (1) WO1988007681A1 (es)
ZA (1) ZA882288B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8087591A (en) * 1990-06-01 1991-12-31 W. Alton Jones Cell Science Center Mammalian adipogenic factors
EP1578367A4 (en) * 2002-11-01 2012-05-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
WO2015138309A1 (en) 2014-03-13 2015-09-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for regulating pancreatic beta cell function using adipsin
DE102014107380A1 (de) 2014-05-26 2015-11-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Verfahren zur Diagnose einer durch den alternativen Weg des Komplementsystems vermittelten Krankheit oder eines Risikos hierfür

Also Published As

Publication number Publication date
NO885360D0 (no) 1988-12-01
EP0382720A1 (en) 1990-08-22
EP0287509B1 (en) 1992-09-16
AU606946B2 (en) 1991-02-21
EP0287509A1 (en) 1988-10-19
ATE80465T1 (de) 1992-09-15
EP0382720A4 (en) 1991-01-02
DK675388A (da) 1988-12-02
DK675388D0 (da) 1988-12-02
DE3874543D1 (de) 1992-10-15
JPH02503229A (ja) 1990-10-04
WO1988007681A1 (en) 1988-10-06
DE3874543T2 (de) 1993-02-04
AU1591388A (en) 1988-11-02
EP0382720B1 (en) 1992-09-09
ES2046325T3 (es) 1994-02-01
FI894592A0 (fi) 1989-09-28
FI894592A (fi) 1989-09-28
NO885360L (no) 1989-02-01
ZA882288B (en) 1988-12-28
GR3005716T3 (es) 1993-06-07

Similar Documents

Publication Publication Date Title
WO1998027227A3 (en) Pharmacogenetic methods for use in the treatment of nervous system diseases
Baly et al. Dissociation of insulin-stimulated glucose transport from the translocation of glucose carriers in rat adipose cells.
GB2205643B (en) Type iii collagen degradation assay
MX9605176A (es) Polimorfismo de apolipoproteina e y tratamiento de la enfermedad de alzheimer.
SE9201573D0 (sv) Use of igf-1
EP0376251A3 (en) An anticoagulant substance obtained from urine
HARRINGTON et al. The association between lichen sclerosus et atrophicus and HLA‐B40
IL85897A0 (en) Method of diagnosing obesity caused by a genetic abnormality
ZA92389B (en) Method for detection of anti-rna-antibodies
Björkholm et al. Immunological defects in healthy twin siblings to patients with Hodgkin's disease
Charpentier et al. Prolidase deficiency with iminodipeptiduria: biochemical investigations and first results of attempted therapy
Nakamura et al. A novel variant of transthyretin (Glu89Lys) associated with familial amyloidotic polyneuropathy
Merluzzi et al. Recovery of the capacity for cytotoxic T cell generation in cyclophosphamide-treated mice by the addition of Lyt-1+ 2− helper cells
SKOUBY Hydroxocobalamin for Initial and Long‐term Therapy for Vitamin B12 Deficiency
Scharf et al. Transverse myelitis with systemic lupus erythematosus
DE3572033D1 (en) Method for diagnosis of a.i.d.s.
SU943578A1 (ru) Способ определени суточной дозы гепарина
ATE141335T1 (de) Verfahren zur bestimmung des cholesterins, zum nachweis von gefässkrankheiten und zur anhebung des anteils an hdl-cholesterin
Goldstein Carbamazepine treatment for stuttering.
UA6102A1 (uk) Спосіб визначення індивідуальної чутливості хворих до кемантану при хронічному обструктивному бронхіті
Yang BIOCHEMICAL CHARACTERIZATION AND GENETIC ANALYSIS OF VITAMIN-B12 BINDING PROTEINS IN HUMAN BLOOD CELLS AND BODY FLUIDS
Fox et al. From the author
KR890005277A (ko) 2본쇄 rna 부족 상태의 진단 및 치료방법
Milovanovié et al. Urinary 5hydroxyindoleacetic acid and serum phenobarbital of children suffering from epilepsy
Van Gaal et al. P. 53 Refeeding in anorexia nervosa